依达拉奉右莰醇注射用浓溶液对比注射用尤瑞克林治疗急性缺血性脑卒中的成本效用分析

Cost⁃utility analysis of edaravone dexborneol versus human urinary kallidinogenase for the treatment of acute ischemic stroke

目的:评价依达拉奉右莰醇注射用浓溶液对比注射用尤瑞克林治疗急性缺血性脑卒中患者的经济性。方法:采用中国医疗卫生体系角度,基于临床试验患者个体数据,采用匹配调整间接比较法调整患者基线特征后对临床疗效指标进行间接比较,构建决策树和Markov模型进行终身模拟,使用成本效用分析比较2种方案的经济性,同时进行单因素敏感性分析和概率敏感性分析验证结果的稳健性。结果:相比注射用尤瑞克林,依达拉奉右莰醇注射用浓溶液组患者获得的质量调整生命年(QALY)为0.332 0,增量成本为539.34元,增量成本效用比为1 624.44元·QALY^(-1),小于1倍2022年我国人均GDP。单因素敏感性分析和概率敏感性分析结果验证了结果的稳健性。结论:与注射用尤瑞克林相比,依达拉奉右莰醇注射用浓溶液治疗急性缺血性脑卒中具有经济性。

Objective:To analyze the cost⁃utility of edaravone dexborneol versus human urinary kallidinogenase in patients with acute ischemic stroke.Methods:From China's healthcare system perspective,based on the individual patient data of clinical trial,the baseline patient characteristics were adjusted by matching⁃adjusted indirect comparison method to indirectly compare clinical efficacy indicators.A decision tree and Markov model were constructed for lifetime simulation,and the cost⁃utility analysis was conducted to compare the economics of the two treatments.One⁃way sensitivity and probabilistic sensitivity analyses were simultaneously performed to examine the robustness of the results.Results:Compared with human urinary kallidinogenase,edaravone dexborneol gained an additional 0.3320 QALYs with an additional cost of 539.34 yuan,yielding an incremental cost⁃effectiveness ratio of 1624.44 yuan per QALY,lower than 1fold of per capita GDP of China in 2022.Conclusion:Compared with human urinary kallidinogenase,edaravone dexborneol is an economic treatment for patients with acute ischemic stroke.